A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2) - BUS-P3-02

Bellus Health Inc.0 个研究点目标入组 771 人开始时间: 2024年7月19日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•1. Between 18 and 80 years of age inclusive 2. Capable of understanding the written informed consent 3. Diagnosis of Refractory chronic cough (including unexplained chronic cough) for = 1 year prior to Screening 4. Participants must meet the cough frequency criteria 5. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to the contraceptive guidance

•1. Current smoker or vaper or current use of tobacco smoke, cannabis smoke, or nicotine vapors or Individuals who have given up smoking or vaping within the past 6 months, or those with > 20 pack-year smoking history 2. Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, or uncontrolled asthma 3. History of upper and/or lower respiratory tract infection or significant change in pulmonary status within 28 days of Screening 4. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection at Screening 5. Medical history of malignancy and treatment completed = 5 years prior to Screening 6. History of a diagnosis of drug or alcohol dependency or abuse within the last 3 years 7. Positive serological test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C at Screening 8. Previous participation in an investigational study of BLU-5937

发起方